Voxilaprevir is a
hepatitis C virus
The hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family ''Flaviviridae''. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepato ...
(HCV) nonstructural (NS) protein
3/
4A protease inhibitor (by
Gilead
Gilead or Gilad (; he, גִּלְעָד ''Gīləʿāḏ'', ar, جلعاد, Ǧalʻād, Jalaad) is the ancient, historic, biblical name of the mountainous northern part of the region of Transjordan.''Easton's Bible Dictionary'Galeed''/ref> Th ...
) that is used in combination with
sofosbuvir
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken Oral administration, by mouth.
Common side effects include fatigue, headache, nausea, and trouble sleeping. Side effects are gen ...
and
velpatasvir
Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
Side effects
Side effects in studies occurred with similar frequencies as in people treat ...
.
The combination has the trade name
Vosevi
Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C viru ...
and received a positive opinion from the European
Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use (CHMP), formerly known as Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on all issues regarding ...
in June 2017.
On 18 July 2017, Vosevi was approved by the US
Food and Drug Administration
The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...
.
FDA approves Vosevi for Hepatitis C
/ref>
References
NS3/4A protease inhibitors
Tert-butyl compounds
{{antiinfective-drug-stub